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Abstract
Human neural progenitors from a variety of sources present new opportunities to model aspects of 
human neuropsychiatric disease in vitro. Such in vitro models provide the advantages of a human 
genetic background, combined with rapid and easy manipulation, making them highly useful 
adjuncts to animal models. Here, we examined whether a human neuronal culture system could be 
utilized to assess the transcriptional program involved in human neural differentiation and in 
modeling some of the molecular features of a neurodevelopmental disorder, such as autism. 
Primary normal human neuronal progenitors (NHNPs) were differentiated into a post-mitotic 
neuronal state through addition of specific growth factors and whole-genome gene expression was 
examined throughout a time course of neuronal differentiation. After four weeks of differentiation, 
a significant number of genes associated with autism spectrum disorders (ASD) are either induced 
or repressed. This includes the ASD susceptibility gene neurexin 1, which showed a distinct 
pattern from neurexin 3 in vitro, and which we validated in vivo in fetal human brain. Using 
weighted gene co-expression network analysis (WGCNA), we visualized the network structure of 
transcriptional regulation, demonstrating via this unbiased analysis that a significant number of 
ASD candidate genes are coordinately regulated during the differentiation process. Since NHNPs 
are genetically tractable and manipulable, they can be used to study both the effects of mutations 
in multiple ASD candidate genes on neuronal differentiation and gene expression in combination 
with the effects of potential therapeutic molecules. These data also provide a step towards better 
understanding of the signaling pathways disrupted in ASD.
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Introduction
Genetic advances in human neuropsychiatric conditions have provided us with a new 
window through which to begin to study and understand these complex diseases. Perhaps 
this is most evident in autism spectrum disorders (ASD) where recent studies have identified 
many relatively rare monogenic causes of ASD, as well as some common variants 
associated with the disease (1–7). These studies have revealed that autism, like other 
neurodevelopmental disorders is genetically very heterogeneous, involving many potential 
mutational mechanisms and potentially distinct molecular pathways (2, 4, 8).
While this complexity may at first appear daunting, the study of monogenic ASD risk genes 
has proven to be instrumental for understanding the basic biology of these genes during 
brain development. Thus, even though many of the more Mendelian forms of ASDs are rare, 
they provide an important opportunity to begin to understand the normal function of these 
autism risk genes and loci through their manipulation in transgenic mice (9–11). Mouse 
models serve an important function in understanding the role of these risk genes in brain 
development and conserved behavioral traits. While extremely useful for understanding 
monogenic disorders, one drawback to the use of mouse as a model is the challenge of 
perturbing multiple genes to mimic the genetics of disease. In addition, lengthy breeding and 
gestational times can also make experimental design prolonged and less amenable to high-
throughput screening. On the other hand, models such as zebrafish (Danio rerio) do allow 
for rapid and high-throughput in vivo screening of genes and small molecules (12).
So, while animal models are necessary for examining circuits and behavior correlates, it is 
likely that no single model of a complex neurodevelopmental disease will completely 
recapitulate the human disorder. In fact, the study of gene expression pathways provides 
mounting evidence that human and mouse have significant areas of divergence. Comparison 
of global differences in gene co-expression between human and mouse revealed many 
instances of human-specific patterns of expression; several of these modules are associated 
with human neurodegenerative disorders that are challenging to model in mice (13). 
Moreover, a specific comparison of human and chimpanzee signaling pathways downstream 
of FOXP2, a transcription factor involved in speech and language, again identified 
differential gene expression and co-expression networks that could be characterized in vitro 
(14). Therefore, even the most closely related species to humans, the chimpanzee, has 
evolved different signaling networks in some cases. Thus, the use of human-derived model 
systems should be considered an important adjunct for a complete understanding of 
neuropsychiatric disorders involving human higher cognition and behavior. In addition, both 
of the studies mentioned above (13, 14), and many others (15–20) highlight how the 
identification of gene co-expression networks can uncover new functional insights—
including genes involved in neurodegeneration or genes involved in human language and 
cognition. Therefore, the employment of a network approach to any gene expression data set 
generated from a human model system is a significant step towards a complete 
understanding of how gene interactions promote a particular function.
One new approach for modeling disease-related phenotypes in human tissue is the use of 
induced pluripotent stem cells (iPSCs) (21). Using this technique, fibroblasts from patients 
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are converted to the cells of interest and the resultant phenotypes analyzed. At least one 
study has used iPSCs to study Rett syndrome, a disorder within the autism spectrum (22). 
Such a process is a step in the right direction as the cells are human and originate from 
specific patient populations. However, working with these cells can be challenging because 
they need to be manipulated genetically to reprogram into a pluripotent state and the 
conversion to neurons can be lengthy and low in efficiency (23). There is little doubt though 
that a thorough comparative study of the gene expression profile of neurons from iPSCs to 
neural tissue from the same individuals will be very useful.
Another potential model system that also has not been well tested, are human cells that are 
derived from brain tissue and grown in vitro. For the study of neurodevelopmental disorders, 
the use of embryonic brain tissue from early brain development provides the advantage of 
capturing the correct time points in development when genetic and environmental insults are 
thought to be causative (24–26). We therefore developed a human neural progenitor system 
to assess the functional genomics of both normal human neuronal development and autism 
using human fetal brain tissue. These normal human neural progenitors, or NHNPs, are 
derived from early human embryos at approximately 8–19 gestational weeks. These cells 
have previously been utilized to examine neuronal phenotypes during Wnt signaling (27), as 
well as targets of the transcription factor FOXP2, recapitulating patterns observed in vivo 
(14). Here, we find that during the differentiation process of NHNPs, many genes already 
previously linked to ASD are highly co-expressed, as assessed using whole genome 
microarrays. Moreover, a number of ASD genes demonstrate conserved patterns of gene co-
expression during the time course of differentiation. Since little is known about the 
transcriptional program accompanying human neuronal differentiation, the comprehensive 
analysis of gene expression reported here provides a foundational tool for assessing the 
interaction of numerous signaling cascades in the pathophysiology of ASD and other 
neurodevelopmental disorders. The ability to easily manipulate gene expression in these 
cells (14) also makes NHNPs attractive for studying the functional consequences of altered 
signaling pathways involved in ASD in human neurons.
Methods and Materials
Cell Culture
NHNP cells were obtained from Lonza or generated as previously described (28, 29). See 
Supplementary Table 1 for detailed cell line characteristics. Cells were used at a low passage 
(30), typically around passage 20. Proliferating cells were grown on tissue culture plates 
coated with 5μg/mL of fibronectin and 50μg/mL of polyornithine. Growth media of 
proliferating cells was Neurobasal A media (Invitrogen) containing 2.5μM heparin, 10% 
BIT (Stem-Cell Tech), 1% Glutamax (Invitrogen) and 2% penicillin and streptomycin. 
Growth media was supplemented every other day with 10 ng/mL of epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF). For differentiation followed by RNA 
extraction, 100,000 cells were plated per well of a 6-well tissue culture dish coated with 
poly-ornithine and laminin. For differentiation followed by immunocytochemistry, 5,000 
cells were plated per well of a 24-well tissue culture dish containing glass coverslips coated 
with poly-ornithine and laminin (5μg/mL). Two days after plating, samples were collected 
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for the undifferentiated, or time zero, time point. At this time, we initiated the differentiation 
process and fed cells with a 50% media change containing retinoic acid (10 ng/mL), 
neurotrophin-3 (NT-3) (10ng/mL), brain-derived neurotrophic factor (BDNF) (10ng/mL), 
and potassium chloride (KCl) (10mM). We continued to provide a 50% media change 
containing these growth factors every other day until the samples were collected. Samples 
were harvested at three time points after initiating the differentiation process: 2 weeks, 4 
weeks, and 8 weeks.
Genetic Association Data
All human transcripts from build hg18 that map to a unique location in the genome were 
utilized. SNPs from the Illumina 550k platform were analyzed from 20k upstream of the 
transcript start site to 10k downstream of the transcript end. P values for association with 
ASD were drawn from the discovery phase of (6), using 780 multiplex families from the 
Autism Genetics Research Exchange (AGRE). Data are included in Supplementary Table 6.
Genotyping
Genomic DNA was extracted from four independently generated cell lines using Qiagen’s 
DNeasy kit according to the manufacturer’s instructions. Approximately 1.5ug of gDNA 
from each line was hybridized to Illumina’s Human CytoSnp-12 genotyping arrays. SNP 
genotypes were filtered for quality and analyzed for gender in PLINK (31). Race 
determinations were made in PLINK using multi-dimensional scaling. Existing genotype 
data (6) and self-reported race information from the AGRE cohort were used to establish 
racial groups. CNVs were called using Penn CNV (32)with wave adjustment and subjected 
to the following quality filters: log R ratio SD <0.28, B allele frequency drift <0.002, 
waviness factor <0.05.
Immunocytochemistry
Coverslips were fixed in 2% PFA in PBS at RT for 10mins and permeabilized in 0.5% 
Triton-X at RT for 10mins. Next, non-specific staining was blocked using TBS containing 
10% normal donkey serum and 0.1% Triton-X at RT for 1hr. Incubations with primary 
antibodies diluted in blocking solution were done at 4C overnight. Incubations with 
secondary antibodies diluted in blocking solution were done at RT for 1hr. Cell nuclei were 
stained using DAPI. Images were captured using a Zeiss Axio Imager. D1. Antibodies 
utilized were: rabbit anti-nestin (1:200, Millipore); mouse anti-Tuj1 (1:2000, Covance); 
Alexa Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 555 donkey anti-mouse IgG 
(1:1000, Invitrogen).
In situ Hybridization
In situ hybridization was performed as previously described (33)using human fetal brain as 
template. Primers are included in Supplementary Table 8. Sense control probes did not show 
any signal (data not shown). Fresh frozen human fetal brains were obtained from the 
University of Maryland Brain and Tissue Bank. Demographics on the fetuses from which 
the brains were derived are as follows: Figure 2B and 2F: #1137, 18GW, Female, African 
American, 2hr PMI; Figure 2C and 2G: #1110, 19GW, Female, African American, 2hr PMI; 
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Figure 2D and 2H: #1010, 20GW, Female, Caucasian, 3hr PMI; Figure 2E and 2I: #1057, 
19GW, Female, African American, 1hr PMI. All fetuses were considered “normal” except 
for #1010, which had polyhydramnios, twin-to-twin transfusion syndrome.
Microarray Analysis
Total RNA was extracted using Qiagen’s RNeasy kit, according to the manufacturer’s 
instructions. Samples were hybridized to Illumina Human Ref8-v3 microarrays. Quantile 
normalization was conducted as previously described (14). Heatmaps and dendrograms were 
generated using the limma package in R. Gene ontology (GO) and disease association 
analysis was done as previously described (14)using DAVID (http://david.abcc.ncifcrf.gov) 
and all of the probes on the microarrays as background. Gene expression data have been 
deposited in the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) 
and are accessible using GEO accession number GSE28046.
qRT-PCR
cDNA was generated from total RNA using random hexamers and Superscript III 
(Invitrogen). Real-time PCR was conducted using Sybr-Rox SuperMix (BioRad) and an 
HT-7900 (Applied Biosystems). Intron-spanning primers are detailed in Supplementary 
Table 8.
WGCNA
Weighted gene co-expression analysis was conducted as previously described (14, 15). See 
supplemental methods for R code used to generate and analyze the network. Genes denoted 
as being implicated in ASD were based on the SFARI gene database (http://gene.sfari.org), 
and are demarcated or used for analysis in Figure 3, Supplemental Figure 2, and 
Supplementary Tables 6 and 7.
Results
We first assessed the feasibility of using NHNPs as a model system for studying neuronal 
differentiation. Low passage NHNPs were utilized for all experiments, and when the cells 
were provided with growth-inducing signals in the form of EGF and bFGF they maintained 
a proliferative state (Figure 1A; see Materials and Methods). While the doubling time of 
these human cells is prolonged compared to embryonic rodent neural progenitors, the 
NHNPs can be kept in culture in a proliferative state for at least a year, if not longer (data 
not shown). We then tested the characteristics of the NHNPs after receiving differentiation 
cues, which was achieved by replacing EGF and bFGF with retinoic acid to promote cell 
cycle exit (see Materials and Methods). In addition, we also supplemented the media with 
BDNF, NT-3, and KCl to provide supportive growth factors and appropriate conductive ions 
for neurons. Under these conditions, we found a three-fold decrease in proliferating, Ki67+ 
cells after two weeks (Figure 1B).
We next assessed whether we could generate neurons under these differentiation conditions. 
We conducted immunostaining for nestin, a marker of proliferating progenitors (34); Tuj1, a 
marker of immature neurons (35); MAP2, a marker of mature neurons (36); and GFAP, a 
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marker of glia (37). We found a significant decrease in nestin-positive cells and a significant 
increase in both Tuj1 and MAP2-positive cells with four weeks of differentiation (Figure 
1C–F and data not shown). Tuj1-positive cells represent about 50% of the cells in culture at 
four weeks (Figure 1F), whereas the number of GFAP-positive cells stayed consistent 
throughout differentiation (data not shown). Thus, using our differentiation conditions, we 
can efficiently differentiate human neural progenitors into post-mitotic neurons. Moreover, 
based on gene expression profiling (see below), the NHNPs may differentiate into a number 
of neuronal types including both excitatory and inhibitory neurons. This is evidenced by an 
increase in expression of genes such as DRD3, DRD4, GABBR1, GABRB3, GAD1, GAD2, 
GRIK1, GRIN1, GRM2, GRM3, SLC23A1, and SLC6A1 for example (Supplementary Table 
2).
Next, we characterized this process of differentiation by conducting whole-genome 
microarray analyses on a time course of differentiating NHNPs. We selected four time 
points to assess: time 0 or undifferentiated cells, two weeks, four weeks, and eight weeks of 
differentiation (T0, D2, D4, and D8). These time points were chosen for the following 
reasons: D2 because we observed a significant decrease in proliferation at this time (Figure 
1B), D4 because there was a significant increase in Tuj1 at this time (Figure 1F), and D8 
because it represented a period of time twice as long as D4 for direct comparison with the 
D2 to D4 transition during neuronal maturation. Four biological replicates from each time 
point were included for analysis. Hierarchical clustering demonstrates that the biological 
replicates clustered with one another and that the time point most different from the other 
three when considering expression of all genes was the one containing the undifferentiated 
cells (Supplemental Figure 1A). When only the top 500 most variable genes were analyzed, 
T0 and D2 clustered separately from D4 and D8 (Supplementary Figure 1B), suggesting that 
the genes changing the most during the time course represent differential patterns of 
expression between the early and late phase of differentiation. This pattern also suggested 
that neural specification may be entrained at time point D4.
To investigate the possibility that D4 was a critical time point in NHNP differentiation, we 
examined the genes changing at D4 compared to T0. Using criteria of a false discovery rate 
(FDR) ≤0.01 together with a fold change of ±1.5, 2218 genes increased in abundance and 
2209 genes decreased at D4 compared to T0 (Figure 1G). Known key markers of neuronal 
differentiation increased at this time point including MAP1B (38), PAX6 (39), SNAP25 (40), 
ephrins (EFNB3, EFNB1) (41), and semaphorins (SEMA5A, SEMA5B, SEMA6C) (42). In 
addition, the expression pattern of genes in the NHNPs is consistent with the cells being 
derived from forebrain progenitors. For example, SP8 and SHH are expressed in the 
proliferating cells (43), whereas RELN, SOX5, TBR1, BCL11B (CTIP2), CALB2, and NGFR 
are induced with differentiation (44). Supplementary Table 2 lists all of the genes changing 
at the D4 time point. Gene Ontology (GO) analysis revealed that the most significantly 
enriched categories for upregulated genes were nervous system development, neurogenesis, 
neuron differentiation, and synaptogenesis while those for downregulated genes were cell 
cycle and mitosis (Table 1 and Supplementary Table 3), consistent with cessation of the 
proliferative state. Disease association data were also derived from the DAVID database 
based on Gene Ontology classifications (see Materials and Methods). All of these data were 
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derived from gene expression profiling in one cell line. However, we found significant 
overlap (P<3.73E-85 – P=0.0) using similar differentiation parameters with two different 
lines of NHNPs (line 4, Supplemental Table 1 and an additional third line, data not shown).
We next compared the genes changing at D4 to those changing at least 1.3-fold in human 
brain in vivo between 18 and 23 gestational weeks (45)to determine to what extent the in 
vitro changes recapitulated those observed in vivo. Out of a potential 575 genes that are 
available for overlap comparison using our criteria for fold change, 167 genes are increased 
(P=7.56E-89) and 202 are decreased (P=5.64E-114) under both maturation conditions 
(Supplementary Table 4), an overlap of about two-thirds. These data are even more 
remarkable considering that the microarrays utilized are different, only a relatively short 
period of in vivo development is represented and the in vivo data for comparison consists of 
pooled data that includes subcortical areas. Thus, these data support the hypothesis that four 
weeks of differentiation of NHNPs recapitulates the appropriate timing for robust neuronal 
differentiation in human cells and tissue and reflects molecular processes relevant to in vivo 
development.
To assess whether this model system could be appropriate for understanding ASD, we cross-
referenced two lists of genes with strong evidence for association with ASD (8, 46) with the 
genes changing during D4 (FDR≤0.01 and fold change ±1.3). Out of a total of 28 genes 
implicated in ASD, we found a significant overlap of genes going both up (7 genes; 
P=2.6E-02) and down (7 genes; P=2.4E-02) at D4 (Table 2). Next, we examined whether we 
could independently confirm the genes changing on the microarrays using real-time RT-
PCR (qRT-PCR). Using a threshold of 1.5-fold change, we confirmed approximately 80% of 
the genes tested (Table 2). Therefore, the microarrays indicate that a significant number of 
ASD candidate genes are regulated during human neuronal differentiation in vitro.
One interesting observation was that neurexin 1 (NRXN1), an autism and schizophrenia 
susceptibility gene, and one probe for neurexin 3 (NRXN3) change in opposite directions on 
the microarrays. We subsequently confirmed by qRT-PCR that NRXN1 was upregulated 
during NHNP differentiation (Figure 2A) consistent with its known role in synaptic function 
(47, 48). However, using three different primer pairs to different NRXN3 isoforms, we found 
NRXN3 was downregulated (Figure 2A). This was somewhat surprising, since there was no 
previous suggestion that these two highly homologous genes had different functions or 
expression patterns in human brain. To see if this corresponded to the in vivo situation, we 
performed in situ hybridization in human fetal brain, which remarkably confirmed these 
results. NRXN3 is expressed in areas of progenitor cells in human fetal brain, while NRXN1 
is expressed in areas of post mitotic neurons (Figures 2B–I). Inspection of the mouse in situ 
hybridization data in Allen Brain Atlas also shows a similar pattern using different probes 
(http://www.brain-map.org/). This proof of principle demonstrates how a simple in vitro 
human system can be used to guide in vivo discovery. These particular data suggest that 
NRXN3 has a previously unknown role in neural progenitor biology, distinct from canonical 
neurexin function at the synapse, which is likely conserved from mice to humans.
While distinct up or down changes in gene expression are important parameters of any 
cellular process, we have begun to appreciate that gene expression datasets contain other 
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inherent patterns of gene co-expression that can be mined, so as to reach new functional 
insights (49). Specifically, we have used weighted gene expression co-expression network 
analysis (WGCNA; (50)) as previously described (14, 15)to provide a systems-level view of 
the organization of the neural transcriptome. Genes that are highly co-expressed are grouped 
into “modules.” Modules’ correspondence to different aspects of function, such as neuronal 
phenotypes, sample characteristics (disease vs. control), or cellular organelles is determined 
by analysis of the module eigen gene or first principle component (15, 50). In addition, 
central or “hub” genes can be identified within modules (15, 20).
WGCNA of the NHNP differentiation time course identified a total of 22 modules, 14 of 
which could be easily characterized (Supplementary Table 5). Four modules were clearly 
associated with differentiation over time throughout the entire time course from T0 through 
D8. Four other modules correlated best with the undifferentiated cells (T0), while one 
module eigengene was highly correlated with D2 and another with D8. The module whose 
eigengene is most correlated with D2 (the green module) is of interest since these genes are 
likely those involved in defining the onset of neural specification and the cessation of 
proliferation and cell division. The D8, or sea green, module may contain genes involved in 
neuronal maturation and phenotype maintenance. Finally, four other modules depicted the 
transition from D2 to D4. We hypothesized that these modules likely contain genes that are 
critical for the differentiation process, as D4 was the time point when a significant increase 
in Tuj1 positive cells was observed (Figure 1) and the GO of genes changing at D4 was 
enriched for CNS differentiation.
We next sought to determine whether there may be shared biological processes or pathways 
between distinct ASD risk genes in an unbiased manner using WGCNA. To broaden the 
number of genes available for this analysis, we queried the SFARI gene database for the 
most inclusive list of genes with a relationship to ASD (http://gene.sfari.org). While many of 
these genes may currently have a weak association to ASD, inclusion of as many genes as 
possible in this analysis should yield networks of genes with the greatest potential for ASD-
related gene co-expression and provides an unbiased view. Using the SFARI database, we 
demarcated 224 genes with a potential role in ASD. Ninety of these genes overlapped with 
the top 6000 most-connected genes in the current gene expression dataset and were included 
in the network analysis. Although these 90 genes were distributed across 17 modules 
(Supplementary Table 6), there were four modules with a particular concentration of ASD 
genes: the royal blue module (with 18 ASD genes), the pink module (with 17 ASD genes), 
the turquoise module (with 8 ASD genes), and the black module (with 7 ASD genes) (Figure 
3). This non-random concentration of genes within this cohort of modules suggested some 
shared pathways and previously un-recognized connections between ASD susceptibility 
genes.
The module eigengene of the royal blue module is related to T0; thus these genes are most 
related to the proliferative state of the neural progenitors. Not surprisingly, therefore, the top 
enriched GO categories for the royal blue module include cell adhesion, nervous system 
development, and neurogenesis (Supplementary Table 3). While none of the ASD genes are 
“hub” (or the most connected) genes in the royal blue module, at least four of the candidate 
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ASD genes, CBS, DLX2, RIMS3 and PRKCB1, are included in the top 250 connections 
within this module (Supplemental Figure 2A).
The pink module contains genes related to differentiation across the entire time course. 
Therefore, these genes are most correlated with the process of differentiation. The pink 
module contains genes that are enriched in cell cycle GO categories (P=2.29E-05) and axon 
guidance (P=1.74E-02) (Supplementary Table 3). Visualization of the top connected genes 
in the pink module reveals ABAT, PLAUR, and SCN1A, all ASD candidate genes, as being 
among the most connected genes within the module (Figure 5B). Interestingly, MET, 
another ASD gene that likely coordinates with PLAUR to transmit hepatocyte growth factor 
signaling (8, 51), is also contained within the pink module, but does not make the cutoff for 
visualization.
The black and turquoise modules contain genes involved in the D2 to D4 transition; 
therefore, these genes are likely to be important for early neuronal differentiation. The black 
module is enriched for genes involved in signal transduction (P=4.53E-07). Two out of the 
seven ASD candidate genes, NRXN1 and GLRA2, can be visualized among the most 
connected genes in the black module (Figure 5C). The most significant GO categories for 
the turquoise module are neuron projection (P=1.27E-06) and nervous system development 
(P=5.41E-06). Both NRXN1 and SLC9A6 are highly connected within the turquoise module 
(Figure 5D). Strikingly, of the almost 600 gene connections to ASD genes within the four 
ASD modules, only seven, or 1%, were previously known or could be surmised based on the 
literature, while the remaining 590 are novel, demonstrating the power of this analysis.
Another manner with which to identify potentially novel ASD signaling pathways is to focus 
on the interconnectedness of only the known ASD genes. For example, upon filtering for 
only known ASD-gene related connections in the turquoise module, not only are the ASD 
genes always connected by one node or fewer, but now other genes are prioritized, such as 
the cell adhesion genes CTNNA2 and TAGLN (Supplemental Figure 2A). Using an identical 
approach with the royal blue module shows inclusion of 17 out of the 18 ASD genes in the 
module (Supplemental Figure 2B). In addition, well-characterized genes such as SEMA5B 
and GFAP are easily identifiable as connected among these ASD genes. This level of 
connectivity is non-random, as the mean overall network connectivity degree is 17 times 
less than the ASD genes alone, and permutation analysis (See Supplemental Methods) 
shows that the ASD gene connectivity is much more significant compared with a 
randomized list of genes of the same size (P=0). This demonstrates that within the complex 
and enormous process of neuronal differentiation, specific aspects and pathways are more 
clearly associated with ASD.
To validate whether there were any genetic associations increased in these four modules, we 
first examined the literature using GO. The royal blue module is enriched for genes with a 
genetic association with schizophrenia (although this P value did not reach our threshold for 
significance; P=5.86E-02). These data make sense in light of some of the overlapin the 
genetic origins of schizophrenia and ASD (52–54). In contrast, other neurological disease 
genes were not significantly enriched, e.g. dementia (P=1.1E-01), Parkinson’s disease 
(P=3.9E-01), or bipolar disorder (P=4.9E-01). The pink module also contains genes that are 
Konopka et al. Page 9
Mol Psychiatry. Author manuscript; available in PMC 2012 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
enriched in schizophrenia (P=2.12E-02). The black module is enriched for genes implicated 
in autism (P=2.45E-02), bipolar disorder (P=2.50E-04), and Alzheimer’s disease 
(P=4.05E-02). Interestingly, the GO analysis reports four additional genes in the autism 
category that were not included in the SFARI.gene database as potential ASD candidate 
genes (BDNF, TH, HLA-DRB4, and NRG1). This highlights that the criteria for inclusion as 
an “autism gene” can vary among databases. Finally, the turquoise module is enriched for 
genes involved in panic disorder (P=1.28E-02) and attention deficit disorder (P=1.56E-02). 
Thus, these data illustrate that there are likely overlapping signal networks during brain 
development that are disrupted in various permutations to lead to a number of 
neuropsychiatric disorders.
Recent studies have shown that although genome-wide association studies (GWAS) may not 
reveal strongly associated genes with large effect sizes in neuropsychiatric disease, overall 
there may be a weaker signal spread across many genes, as has been demonstrated in 
schizophrenia and bipolar disorder (6, 7, 55). Thus, it has been suggested that identification 
of potentially causal pathways could be a means with which to increase power to detect 
genetic association. To further assess whether there is independent genetic evidence for 
pathway enrichment, we tested for enhancement of genetic association signals for ASD 
within the four modules defined above. When the genes used for network analysis were 
analyzed for genetic association to ASD over 50% of genes with a P Value < 1.0E-02 fell 
into one of these four modules (Supplementary Table 6). While this percentage of genes is 
not statistically enriched, it provides another level of information for prioritizing 
unannotated genes that are highly connected to known ASD genes in these modules.
Discussion
The use of human neural progenitors is an important asset for uncovering the genomic 
patterns of expression in normal human neuronal differentiation and for the study of 
neuropsychiatric diseases. These cells recapitulate the morphology and markers of 
differentiation observed in other model systems. However, the use of a few cell markers is 
limiting, and screening the cells one gene at a time for possible usefulness in the study of a 
particular disease is tedious. Whole-genome expression profiling is a powerful tool for 
viewing the entire transcriptional program of a model system under various conditions. 
Transcriptional profiling has proven extremely informative in the study of many diseases of 
the CNS as well as in understanding the development and evolution of the brain (49, 56). 
We therefore employed a model system of human neuronal cells in combination with whole 
genome profiling and observed an enrichment of the expression of the genes and signaling 
pathways involved in ASD, and to a lesser extent other psychiatric disorders with a 
neurodevelopmental origin, such as schizophrenia. The expression of many of these genes is 
modulated during neuronal differentiation, lending credence to the neurodevelopmental 
origin of ASD (57). Moreover, ASD genes cluster non-randomly in modules of gene co-
expression leading to the potential identification of additional genes with links to ASD. The 
ease with which gene expression can be manipulated in these cells (14)makes them an 
attractive tool for studying signaling pathways involved in ASD and other 
neurodevelopmental disorders.
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As mentioned above, the expression pattern of genes such as SHH and RELN in the NHNPs 
suggests that the cells are derived from forebrain progenitors. Since one of the underlying 
pathologies of ASD is thought to be a developmental disconnection syndrome involving 
frontal –cortical and frontal -subcortical pathways (25, 58, 59), the use of cells derived from 
human fetal cortex provides a potentially powerful and efficient method of examining 
signaling pathways disrupted in the disease. Moreover, it has also been postulated that ASD 
is a disorder of axon outgrowth and/or neuronal migration due to the number of cell 
adhesion molecules that have been implicated in the disorder (60, 61). In line with this, we 
have found a significant enrichment of genes involved in cell adhesion that are changing 
with differentiation (Supplementary Table 3) such as CDH1, FBLN2, NRG1, several 
laminins and numerous protocadherins. In addition, cell adhesion genes are also highly 
enriched within all four ASD modules identified, and cell adhesion is the most significantly 
enriched biological process category in the royal blue module (Supplementary Table 7), 
which is also enriched in ASD candidate susceptibility genes. Parsing the gene expression 
data to identify groups of genes involved in a particular cellular function should prove useful 
as the genetic causes of many of the subtypes of ASD are uncovered. For example, these 
data can be connected to future genes associated with immune dysfunction or head 
circumference in ASD. In addition, perturbation of ASD genes can reveal potential shared 
common pathways within the rubric of the normal network topology.
Here, we study ASD as a prototypical neurodevelopmental disorder for the examination of 
signaling pathways. Many of the genes associated with ASD have known roles in normal 
brain development and have been associated with other neuropsychiatric diseases such as 
schizophrenia (54, 62, 63). Thus, this model system should also serve the study of other 
neurodevelopmental disorders such as epilepsy, or intellectual disability (ID) well. To this 
end, we have uncovered at least one module of gene co-expression containing an enrichment 
of epilepsy genes (64), the pink module, which is also one of the ASD-associated modules 
identified (Supplemental Table 6). This is not surprising given the high co-morbidity of 
these neurodevelopmental disorders, with between 10–25% of ASD patients experiencing 
seizures or epilepsy (65). In addition, genetic data support common causal etiologies for 
these disorders in several cases (66–70). Moreover, GO analyses highlights an enrichment of 
genes with known associations to schizophrenia or other neuropsychiatric disorders.
The application of network analysis to these data can yield important biological insights. 
Not only does WGCNA highlight the interconnectedness of known ASD genes in this model 
system (Supplementary Figure 2), it also serves to uncover potentially novel genes that may 
be affected in the disorder. By conducting our own analysis of publicly available ASD 
association data, we show that the majority of the most significant SNPs are associated with 
genes in our four ASD modules (Supplementary Table 6; See Materials and Methods). 
These data illustrate that the combination of genetic and genomic data is a powerful tool for 
identifying new genes in a disorder, particularly for those that might not make a statistical 
threshold using only one of the methods. For example, while CTNNA2 has been previously 
associated with schizophrenia (71) and attention deficit hyperactivity disorder (72), it has no 
known association with ASD. However, we find it co-expressed with five ASD genes in the 
turquoise module (CACNA1C, FRMPD4, HS3ST5, NRXN1, and SLC9A6) and exhibiting a 
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suggestive association signal with ASD (4.77E-04). Thus, our analysis would suggest that 
CTNNA2 has a high probability of playing a role in ASD and is a good candidate for re-
sequencing in affected patients. In addition to using genetic association data for prioritizing 
candidate genes, future studies can employ the wealth of gene dosage information in ASD 
becoming available (e.g. (1, 2)) to further rank genes in terms of potential pathogenicity.
In addition, we have previously shown that co-expression can be used to annotate gene 
function (15, 17). For example, highly co-expressed genes in the human brain transcriptome 
are also physically co-expressed at the protein level in an adult human neural stem cell niche 
(15). Through the principle of guilt by association we can identify and annotate new gene 
functions. This is based on the hypothesis that similar expression levels among the most 
highly co-expressed genes in a module are the result of shared regulatory mechanisms. Thus, 
it is likely that some of the genes co-expressed with the ASD genes in the NHNPs are also 
key physical partners of the ASD genes in performing certain intrinsic neurobiological 
features in vivo. This fits with both the synapse and developmental dysconnection models of 
ASD. Genes correlated with known ASD genes found at the synapse such as NRXN1 
(73)and RIMS3 (74)could themselves bekey players in synapse biology. For example, both 
NRXN1 and SLC9A6 are co-expressed with FLJ30596 (or c5orf33). Currently, there is 
nothing known about the biology of FLJ30596, however, the expression of SLC9A6 in 
endosomal vesicles (75)and NRXN1 at the synapse suggests that FLJ30596 may also have 
some role in synaptic function. Remarkably, we also find that NRXN3 shows an inverse 
expression pattern to NRXN1, suggesting a role in progenitor biology, which is validated in 
vivo in human fetal brain. In a similar vein, genes correlated with known ASD genes that are 
integral in axon path finding and hence cortico-cortico connections such as EPHA6 (76), 
NRP2 (77), and SEMA5A (78) (Supplementary Table 6) may themselves be involved in such 
processes. Thus, the network approach to gene expression analysis may not only identify 
novel disease-related genes but also may point to the functional role of previously 
uncharacterized genes.
One area of neuropsychiatric research in need of increased innovation is the discovery of 
novel therapeutics. Understanding the genes involved in a disorder is a necessary first step; 
however, having an appropriate model within which to test new drugs is the next critical 
step. The use of the NHNP system fulfills both criteria. Here, we have demonstrated that 
there are robust gene expression changes during the differentiation process that follow what 
is known in vivo in other model organisms as well as in developing human fetal brain. While 
we have found significant overlap with these model systems and in vivo expression, the 
expression of some genes that do not agree (e.g. genes going in the opposite direction in 
Supplementary Table 4) may provide insight into the limitations of this model system and 
should also be considered in future functional studies. In particular, the effects of processes 
such as imprinting on cultured cells versus intact or dissociated tissue is an important caveat 
of this study that may be able to be teased apart using this information. Nonetheless, many 
of the genes in agreement are not only important for normal differentiation, but are also 
disrupted or are co-expressed with genes that are disrupted in ASD. Combining these data 
with previously published (6) and ongoing GWAS in ASD and other neuropsychiatric 
diseases (79) will solidify the role of particular genes and pathways in the disease. 
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Moreover, as the cells are genetically tractable through modification by lentiviral over-
expression or knockdown, multiple genes can be modified simultaneously to mimic the 
genetic heterogeneity of diseases such as ASD. Then together with high-throughput 
chemical library screenings (80), therapeutics for particular genetic signatures can be rapidly 
tested. This combinatorial approach therefore is particularly advantageous over animal 
models where only one or a few genes can be modified concurrently, or high-throughput 
chemical screening is time intensive.
The combination of these human tools with non-human models clearly provides a 
synergistic approach for elucidating the signaling cascades important in both normal human 
brain development as well as in neuropsychiatric disorders. Datasets such as the one 
presented here will identify new disease-related genes and present opportunities for the 
testing and development of personalized therapeutics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of NHNPs
A) NHNPs are mitotically active in the absence of differentiation growth factors. Growth 
curve of proliferating cells. Error bars are ± s.e.m., n=5. B) NHNPs can be induced to a 
post-mitotic state using the right combination of differentiation cues. The number of Ki67+ 
cells decreases at least three fold within two weeks. Error bars are ±s.e.m., n=3. C–E) 
NHNPs display markers and morphological characteristics of neurons with differentiation 
from zero weeks (C) to two (D) and four weeks (E). Green is nestin-positive staining 
denoting uncommitted progenitors. Red is Tuj1-positive staining marking neurons, and blue 
is DAPI. F) The percentage of nestin-positive cells significantly decreases with four weeks 
differentiation whereas the percentage of Tuj1-positive cells increases. Asterisk indicates 
P≤0.005, double asterisk denotes P≤0.001, and error bars are ±s.e.m. (ANOVA, n=4). G) 
Table showing the number of genes changing at each time point comparison using 
microarrays with thresholds of an FDR ≤0.01 and fold change ±1.5.
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Figure 2. Inverse expression patterns of NRXN1 and NRXN3
A) qRT-PCR of NRXN1 and NRXN3 shows an increase in NRXN1 and a decrease in NRXN3 
with differentiation at four weeks in NHNPs. Three different primer pairs amplifying either 
the 5′ end of isoforms 2 and 3 or isoform 1, and the 3′ end of all isoforms of NRXN3 were 
used. In situ hybridization of NRXN1 (B–E) and NRXN3 (F–I) in human fetal brain 
demonstrates an enrichment of NRXN1 in areas of post-mitotic neurons whereas NRXN3 is 
expressed in proliferative areas. Gestational week age of tissue is 18 weeks (B and F), 19 
weeks (C, E, G, and I), and 20 weeks (D and H). Both coronal (B, C, F, and G) and sagittal 
(D, E, H, and I) were used. CP=cortical plate, GE=ganglionic eminence (L=lateral, 
M=medial), Hp=hippocampus, Str=striatum, Th=thalamus. Scale bars=5mM.
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Figure 3. Network visualization of modules containing ASD genes
A) Royal blue module. B) Pink module. C) Black module. D) Turquoise module. Color 
names are randomly assigned to each module for descriptive purposes. ASD genes are in 
blue and hub genes are depicted in purple. Lines represent connecting edges in the network 
based on topological overlap. The top 250 connections are depicted and line length and 
thickness are arbitrary.
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Table 1
Most significantly enriched gene ontology (biological function) and disease categories of differentially 
expressed genes at D4 compared to T0
Upregulated genes at D4 vs T0
Gene Ontology Category Count PValue
nervous system development 195 2.79E-17
neurogenesis 111 1.06E-10
neuron differentiation 84 5.52E-09
synaptogenesis 16 1.21E-07
neuron development 66 1.77E-07
cell development 104 5.78E-07
cell morphogenesis involved in differentiation 51 6.90E-07
negative regulation of cellular process 221 1.65E-06
cell morphogenesis 64 4.78E-06
neuron projection morphogenesis 44 5.94E-06
Disease Association Count PValue
schizophrenia 56 3.40E-04
Parkinson’s disease 27 5.76E-03
deafness 4 1.60E-02
measles 5 1.82E-02
frontotemporal lobar degeneration 3 4.30E-02
epilepsy, temporal lobe 4 4.63E-02
ALS/amyotrophic lateral sclerosis 7 4.79E-02
Downregulated genes at D4 vs T0
Gene Ontology Category Count PValue
cell cycle phase 115 4.93E-26
M phase 96 1.67E-23
DNA metabolic process 117 3.17E-20
nuclear division 71 6.11E-20
mitosis 71 6.11E-20
M phase of mitotic cell cycle 71 1.09E-19
sterol biosynthetic process 19 4.31E-10
regulation of cell cycle 67 2.20E-08
interphase 31 5.89E-08
interphase of mitotic cell cycle 30 1.09E-07
Disease Association Count PValue
colorectal cancer 39 8.51E-05
breast cancer 48 4.99E-04
methotrexate toxicity 7 2.74E-03
drug hypersensitivity 7 4.01E-03
neural tube defects 11 4.40E-03
lymphoma, non-Hodgkin 9 1.45E-02
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Upregulated genes at D4 vs T0
Gene Ontology Category Count PValue
lung cancer 26 2.92E-02
nemaline myopathy 3 3.04E-02
folate, erythrocyte homocysteine thromboembolism 3 3.04E-02
methotrexate efficacy 3 3.04E-02
stomach cancer 17 3.49E-02
leukemia 15 3.85E-02
bladder cancer 17 4.49E-02
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Table 2
Expression and confirmation of ASD-candidate genes during differentiation
Fold Change
D4 vs T0
Microarrays Pvalue FDR
Fold Change
D4 vs T0
qRT-PCR
A2BP1 1.78 7.79E-05
AHI1 −2.14 8.23E-08 1.06
AUTS2* 1.95 1.67E-09 3.64
CACNA1C 1.44 9.45E-03 21.82
CADPS2 −1.06 6.28E-01
CNTNAP2 −1.19 2.97E-01
CYFIP1 −1.18 6.21E-02
DHCR7 −3.75 5.41E-11 −3.66
EN2 1.18 1.34E-01
FMR1 −1.06 6.06E-01
FZD9* −2.28 2.28E-10 −2.44
GABRB3 1.86 8.93E-07 5.60
GRIK2 −1.18 7.43E-02
LIMK1* −1.77 9.70E-06 −1.58
MECP2 1.72 4.77E-03 3.28
MET −1.45 3.06E-03
NLGN3 −1.33 4.90E-04 1.18
NLGN4X 1.16 6.27E-02
NRXN1 4.33 4.48E-10 46.40
OXTR 1.06 7.60E-01
PLAUR −7.08 4.19E-13
PRKCB1 −6.28 4.37E-13
PTEN 1.53 2.16E-06 3.37
RELN 1.22 1.38E-02
SERPINE1 −10.19 9.07E-13
SHANK3 1.32 1.66E-03 2.36
SLC25A12 1.09 3.20E-01
SLC6A4 −1.01 9.63E-01
TSC1 1.66 1.50E-04 2.05
TSC2 1.27 1.29E-02
UBE3A −1.32 5.58E-05 2.04
*Genes not included in refs 8 and 46, but identified through the SFARI database and confirmed by RT-PCR (http://gene.sfari.org)
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